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USE OF MONOCLONAL ANTIBODY THERAPY
IN CD20+VE FOLLICULAR LYMPHOMA
J Murdock, T C M Morris; Department of
Haematology, Belfast City Hospital.
Rituximab (Rituxan) is a genetically engineered
chimericmurine/humanmonoclonalantibodyand
thefirstmonoclonalantibodytobecomeavailable
to physicians for the treatment of malignant
disease. It has recently been licensed for use in
the treatment of patients with relapsed or
refractory low-grade orfollicular, CD20positive
B-cell Non-Hodgkins Lymphoma (NHL). Its
mechanism of action is by binding to CD20
antigen on the B-lymphocytes and effecting cell
lysis by possible complement activation and/or
antibody-dependentcellularcytotoxicity. Several
clinical trials have been able to show a moderate
to limited response to Rituximab treatment in
patients with relapsed follicular NHL with a 6-
9% complete remission (CR) and up to 50%
partial remission (PR).
We have treated four patients with Rituximab
since April 1998. This group ofpatients (median
age 56; range 51 to 65 years) all had CD20+ve
low-to-intermediate grade NHL which had
relapsed despite several cycles ofchemotherapy.
Eachpatienthadcytopeniaorotherfactorscontra-
indicating intensive second line therapies. All
patientsweretreatedwithintravenousRituximab
at a close of 375 mg/M2 and were premedicated
with chlorpheniramine and paracetamol. Two
patients had no side effects whatsoever, while a
further two complained of mild abdominal
discomfort (1) and dizziness, minor tongue
oedema and pruritus (1). One patient (treatment
commenced April 1998) has shown a subjective
andobjective response to treatmentwithobvious
shrinkage of cervical, axillary and inguinal
lymhadenopathy (PR) within one month of
treatment. He remains well with no palpable
lymphadenopathy 6 months post-treatment.
Another patient has shown a moderate response
with some shrinkage of intra-abdominal nodes,
but with further progression of pelvic
lymphadenopathy on follow-up CT scanning. A
further patient remained symptomatically
unchanged (with no change in disease on CT),
and a fourth patient had progressive disease
despite treatment.
At present treatment with Rituximab is a fairly
costly option and therefore protocols should be
drawnupregardingwhichpatients aremostlikely
to benefit from this novel therapy.
ANTIBODIES FOR IMMUNOSTAINING OF
BOUIN'S-FIXED BONE MARROW BIOPSIES
Colette Murphy, D S O'Briain
Histopathology Department, St James's Hospital and
Trinity College Medical School, Dublin.
Bouin'sfluidiswidelyusedas afixativeforbone
marrow biopsies because it gives excellent
morphology and is easy to use, but it has been
suggestedthatmany antibodies, andinparticular
the much-used B cell markerL26 (CD20), fail to
stain in tissue fixed in Bouin's fluid.
We reviewed all immunostains done on bone
marrow biopsies during a one year period with
particular reference to L26. There were 104
biopsies in all of which successful staining was
presentand inwhich awide variety ofantibodies
had been used including CD45, CD3, CD79a,
CD45RO. There wasconsistently strong staining
forL26in allbiopsies which involvedtheplasma
membrane and cytoplasm of small lymphocytes
and lymphoma cells. Prominent cytoplasmic
processes were noted in many positive cells.
Weak to moderate staining ofblast cell nucleoli
and of megakaryocytes was frequently seen but
could easily be distinguished from positive
lymphoid cells. L26 was particularly useful in
identifying thedegreeofresidualdiseaseinhairy
cell leukaemia treated with 2-
chlorodeoxyadenosine.
This study indicates that in addition to its
morphological benefits, Bouin's fluid is an
excellent fixative for immunostaining using a
wide variety of antibodies.
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ASSESSMENT OF c-erbB-2 EXPRESSION AND
ADVERSE HISTOLOGICAL FEATURES IN
PREINVASIVE AND MICROINVASIVE
SQUAMOUS CERVICAL CANCER
D Butler, E W Kay, C Barry Walsh, M Leader
Department of Pathology, Royal College of Surgeons in
Ireland, St Stephen's Green, Dublin 2.
Amplification and overexpression of c-erbB-2
has been reported in a variety of tumours
predominantly ofepithelial origin such asbreast,
ovary,pancreasandstomach. Membrane staining
forc-erbB-2 has been found to be prognostically
significant. Few studies have addressed the role
of c-erbB-2 overexpression in preinvasive and
invasive squamous cervical lesions and none in
relation to poor histological features.
Eighty-three archival cervical LLETZ biopsies
consisting of27 CINI cases, 30 CIN3 cases and
26 microinvasive cases were selected
consecutively from a computerised database of
casesinthePathologyDepartment,RCSISections
were immunostained for c-erbB-2 oncoprotein
overexpression using an indirect ABC technique
on 3,um sections.
Haematoxylin and eosin stained sections from
the 83 cases were reviewed for the presence of6
histological features some of which have been
previously shown to be associated with
microinvasive cancer namely: extent of surface
involvement, extent of glandular involvement,
comedo necrosis, squamous maturation,
koilocytic change and apoptosis. Univariate and




a statistical relationship with koilcytic change.
All of the histological features examined were
shown to have a strong statistical relationship
with grade of tumour.
Stainingforc-erbB-2incervicalbiopsies appears
tobeoflimiteduse; howeverrecording ofcertain
histological features particularly intralesional
squamous maturation, may be a move useful
indicator of progression.
DETECTION AND SPECIATION OF
CRYPTOSPORIDIUM PARVUM,
CRYPTOSPORIDIUM MURIS, CYPTOSPORIDIUM
BAILEYI AND CRYPTOSPORIDIUM WRAIRI IN
ENVIRONMENTAL WATER SAMPLES USING
IMMUNO-MAGNETIC SEPARATION, PCR AND
ENDONUCLEASE RESTRICTION.
C J Lowery,1'2 J E Moore,2 B C Millar,2
J S Dooley'
1. Department of Applied Biological and Chemical
Sciences, University of Ulster, Coleraine, Northern
Ireland BT52 ISA
2. Northern Ireland Public Health Laboratories,
Department of Bacteriology, Belfast City Hospital,
Lisburn Road, Belfast BT9 7AB Tel. (01232) 329241
Ext 3239 Fax (01232) 321084.
The protozoan parasite Cryptosporidium has
recentlybeenrecognisedasanimportantagentof
gastrointestinal disease leading to a chronic, life
threatening condition in immunocompromised
individuals and to acute gastroenteritis and
diarrhoea in healthy people.
Inrecentyearstherehas been adramatic increase
intheincidence ofwaterborne Cryptosporidiosis
associated with the contamination of drinking
water with human or animal faeces although the
relativecontributionofeachis,however,currently
unknown. Co-infection with Giardia and
Campylobacteralsosuggestscontaminatedwater,
fruit and vegetables and person-to-person as
common modes of transmission. Because the
conventionalindicatorsofmicrobialwaterquality
do not necessarily correlate with the presence or
concentrations of Cryptosporidium accurate
identification ofits modes oftransmission are of
critical importance inevaluating watertreatment
procedures and the public health risk to
cryptosporidiosis.
The current techniques for isolating
Cryptosporidium from water involve filtration
and centrifugation on sucrose gradients to
concentrate and purify oocysts, followed by
immunofluoresence microscopy. Disadvantages
ofthis method include low recovery efficiencies
ranging from 80 to less than 1%, long processing
times, the need for a highly trained analyst, high
cost, an inability to discriminate between
pathogenic and non-pathogenic species, an
inability to determine viability and non-specific
antibody binding.
Agenus-specific PCR assay was designed forthe
specific amplification of a 552bp region of the
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18SrRNAgene.Post-amplificationendonuclease
restrictiongenerateduniquedigestpatternswhich
enableddifferentiation between the four species,
Cryptosporidiummuris, Cryptosporidiumbaileyi,
Cryptosporidium wrairi and Cryptosporidium
parvum, the major human pathogen. The assay
routinely detected 10 oocysts in purified oocyst
preparations but sensitivity was found to be 103-
1 4foldlowerinenvironmental samples although
inhibition was ameliorated by the use of Chelex
resin and an immunomagnetic separation
procedure.Rapidandsensitivepathogendetection
methods are essential for the water industry and
theresultsdemonstratethatPCRhasthepotential
to improve greatly current detection capabilities.
SEROPREVALENCE OF CAMPYLOBACTER
ANTIBODY IN THE NORTHERN IRELAND
POPULATION
J Glenn,' J E Moore,' H Ball,2 P Mallon,'
L Crothers,' P G MurphyI
1. Northern Ireland Public Health Laboratory, Belfast
City Hospital.
2. Department of Bacteriology, Veterinary Sciences
Division, Department of Agriculture for Northern
Ireland, Stormont, Belfast.
Campylobacterjejuni is the most common cause
of acute bacterial gastroenteritis within the
Northern Ireland population, with present
infection rates approximating 25 cases per
100,000 individuals. This is in contrast to
populations from England and Wales and also
Scotland, where the infection rates are circa 75
and 120 cases per 100,000 individuals
respectively. The aim of this study was to
determine the seroprevalence of Campylobacter
antibody in the Northern Ireland population,
which may in turn be useful in demonstrating
epidemiologicaldifferencesbetweenpopulations
amongst the various regions within the UK.
Previous research has indicated the lower
incidence of this disease within this population,
and the most up to date figures mirror this
statement.
A locally developed monoclonal antibody was
employed in an ELISA assay, derived from a
common outer membrane protein in C. jejuni.
The 5A7 monoclonal was developed using the
OMP 18 antigen and following bulk growth of
clones, ascites was then produced; caprylic acid
purified and used for plate coating. From initial
determinations using preliminary ELISAs with
coating of 1/100 of the purified monoclonal for
capturing the antigen and the use of crude
Campylobacter antigens, it is possible to detect
thetestpositivehuman seraatadilution of 1/400.
Two human populations were examined in this
study, namely (1) serum from ill patients, where
a serological test was requested (n = 500) & (2)
serumfrom"healthy" individuals donatingblood
totheNorthernIrelandBloodTransfusionService
(NIBTS) (n =130). Positive controls were taken
as serum from hospitalised patients with a well-
characterisedepisodeofCampylobacterenteritis.
Negative controls were selected from patients
withX-linked agammaglobulinaemia(XLA) and
common variable immunodeficiency (CVI), not
onreplacementimmunoglobulintherapy. Results
indicate there is a markedly low seroprevalence
of IgG antibody in the healthy population.
Statistically,inthepatientpopulationsignificance
was found in the older female population (p<
0.005) in the 41-50 and 61-70 age groups.
Seroprevalence between age groups was
significant in males between the 11-20 and the
51-60 age groups.
Overall, itappears thatthere is alow incidence of
CampylobacterIgGantibodywithintheNorthern
Ireland population, hence indicating a lower
exposure and hence lower level of infection by
the organism.
Further investigations leading from this study
should include the examination of different
conjugatesinordertoclassifytheinfectionleading
to the presence ofantibody in the sera samples as
being recent infection (IgM), current infection
(IgA) or previous infection or a secondary
exposure (IgG) from the bacterium.
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